Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Cipla Chief Calls For Invigorating Focus On Repurposed Drugs

Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
Research & Development India

Glenmark Spins Out Innovation With New US Base

Glenmark’s innovation business will now be housed in a spin-out arm, based in the US, where the Indian parent believes the ecosystem is more conducive to cutting-edge R&D. The new structure could also potentially provide new opportunities to unlock value for the parent company.
Commercial Strategy

Sun’s Ilumya Gnaws At US Psoriasis Market

Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.

Commercial Strategy

Dr Reddy's Brings In Kikuchi To Lead North America Generics

Dr Reddy’s has added to its senior leadership team by appointing Marc Kikuchi as CEO of North America Generics. With a record number of US launches in Q3, potentially more in store and now a new leader to steer things through, the firm has improved its outlook for a significant revival in earnings. But risks of delays and competition on certain key anticipated launches in 2019 could dull prospects.

Appointments North America

API Sector In India No Longer ‘Poor Cousin’ Of Formulations

The active pharmaceuticals ingredients segment in India appears to be coming into its own, alongside signs of a revival in the overall sales growth of Indian generic firms in FY2019, a study by an Indian investment banking and consulting services firm has indicated.

Ingredients Market Intelligence

Patent Rebuff For Roche’s Valcyte In India, Again

Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.

Intellectual Property India
See All
Advertisement
UsernamePublicRestriction

Register